References
- Nicholson B, Ross E, Sasaki J, et al. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 2006;22:1503–14
- Adams D, Gunyea I, Bhakta B, et al. Retrospective assessment of frequency of dosing of sustained release opiate preparations in chronic pain patients [abstract]. Pain Med 2002;3:185
- Marcus DA, Glick RM. Sustained-release oxycodone dosing survey of chronic pain patients. Clin J Pain 2004;20:363–6
- Ackerman SJ, Mordin M, Reblando J, et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 2003;9:223–33
- American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 2003; Glenview, Ill: American Pain Society
- Rauck RL, Bookbinder SA, Bunker TR, et al. The ACTION study: a randomized, open-label, multicenter trial comparing once-aday extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain. J Opioid Manage 2006;2:155–66
- Rauck RL, Bookbinder SA, Bunker TR, et al. A randomized, open-label study of once-a-day AVINZA® (morphine sulfate extended-release capsules) versus twice-a-day OxyContin® (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial. J Opioid Manage 2006;2:325–33